Amicus Therapeutics announces planned analysis of primary endpoints in phase 3 study
Amicus Therapeutics has completed the analysis plan for the primary endpoints in the blinded ongoing Phase 3 clinical study of the novel topical medicine SD-101 for epidermolysis bullosa. SD-101 was one of the first treatments to receive the FDA's Breakthrough Therapy designation. May 19, 2017